Outcome Capital Congratulates Elios Vision on the Acquisition by Bausch + Lomb
Outcome Capital announces the successful acquisition of Elios Vision by Bausch + Lomb (NYSE/TSX: BLCO). Elios Vision, a developer of minimally invasive glaucoma surgery (MIGS) using excimer laser technology, has created the ELIOS™ procedure, an implant-free treatment designed to reduce intraocular pressure in glaucoma patients while minimizing risks associated with traditional surgeries.
The technology is currently CE-marked and available in the European Union, with FDA approval being sought this year. The procedure can be performed standalone or alongside cataract surgery, offering broader adoption potential due to its relative simplicity compared to implant-based MIGS. The acquisition strengthens Bausch + Lomb's position in the $2.5 billion glaucoma treatment market, addressing a condition that affects over 76 million people globally.
Outcome Capital annuncia l'avvenuta acquisizione di Elios Vision da parte di Bausch + Lomb (NYSE/TSX: BLCO). Elios Vision, sviluppatore di interventi chirurgici per il glaucoma minimamente invasivi (MIGS) utilizzando la tecnologia del laser eccimeri, ha creato la procedura ELIOS™, un trattamento senza impianti progettato per ridurre la pressione intraoculare nei pazienti affetti da glaucoma, riducendo al contempo i rischi associati alle chirurgie tradizionali.
La tecnologia è attualmente contrassegnata CE ed è disponibile nell'Unione Europea, con l'approvazione della FDA in fase di richiesta per quest'anno. La procedura può essere eseguita in autonomia o insieme a un intervento di cataratta, offrendo un potenziale di adozione più ampio grazie alla sua relativa semplicità rispetto ai MIGS con impianto. L'acquisizione rafforza la posizione di Bausch + Lomb nel mercato del trattamento del glaucoma da 2,5 miliardi di dollari, affrontando una condizione che colpisce oltre 76 milioni di persone in tutto il mondo.
Outcome Capital anuncia la exitosa adquisición de Elios Vision por parte de Bausch + Lomb (NYSE/TSX: BLCO). Elios Vision, desarrollador de cirugía mínimamente invasiva para el glaucoma (MIGS) utilizando tecnología de láser excimer, ha creado el procedimiento ELIOS™, un tratamiento sin implantes diseñado para reducir la presión intraocular en pacientes con glaucoma mientras minimiza los riesgos asociados con las cirugías tradicionales.
La tecnología está actualmente marcada con el CE y disponible en la Unión Europea, mientras que se busca la aprobación de la FDA este año. El procedimiento se puede realizar de forma independiente o junto con la cirugía de cataratas, ofreciendo un mayor potencial de adopción debido a su relativa simplicidad en comparación con los MIGS basados en implantes. La adquisición fortalece la posición de Bausch + Lomb en el mercado de tratamiento del glaucoma de 2.5 mil millones de dólares, abordando una condición que afecta a más de 76 millones de personas en todo el mundo.
아웃컴 캐피탈은 Bausch + Lomb (NYSE/TSX: BLCO)가 Elios Vision을 성공적으로 인수했다는 소식을 발표했습니다. Elios Vision은 엑시머 레이저 기술을 사용하여 최소 침습성 녹내장 수술(MIGS)을 개발한 회사로서, ELIOS™ 절차를 창안했습니다. 이 절차는 임플란트가 필요 없는 치료로, 녹내장 환자의 안압을 낮추면서 전통적인 수술과 관련된 위험을 최소화하도록 설계되었습니다.
이 기술은 현재 CE 마크를 획득하였으며 유럽 연합에서 사용 가능합니다. 또한 올해 FDA 승인을 받을 예정입니다. 이 절차는 독립적으로 수행할 수 있거나 백내장 수술과 함께 진행될 수 있어, 임플란트 기반 MIGS에 비해 상대적으로 단순하다는 이유로 더 넓은 채택 가능성을 제공합니다. 이 인수는 25억 달러 규모의 녹내장 치료 시장에서 Bausch + Lomb의 입지를 강화하며, 전 세계 7,600만 명 이상의 사람들에게 영향을 미치는 질환을 다룹니다.
Outcome Capital annonce l'acquisition réussie de Elios Vision par Bausch + Lomb (NYSE/TSX: BLCO). Elios Vision, développeur de chirurgie glaucomateuse minimalement invasive (MIGS) utilisant la technologie au laser excimer, a créé la procédure ELIOS™, un traitement sans implant conçu pour réduire la pression intraoculaire chez les patients atteints de glaucome tout en minimisant les risques associés aux chirurgies traditionnelles.
La technologie est actuellement marquée CE et disponible dans l'Union Européenne, avec une demande d'approbation de la FDA prévue pour cette année. La procédure peut être effectuée de manière autonome ou en parallèle avec une chirurgie de la cataracte, offrant un potentiel d'adoption plus large grâce à sa relative simplicité par rapport aux MIGS basés sur des implants. Cette acquisition renforce la position de Bausch + Lomb sur le marché des traitements du glaucome de 2,5 milliards de dollars, portant sur une condition qui affecte plus de 76 millions de personnes dans le monde.
Outcome Capital gibt die erfolgreiche Akquisition von Elios Vision durch Bausch + Lomb (NYSE/TSX: BLCO) bekannt. Elios Vision, ein Entwickler von minimal-invasiven Glaukom-Chirurgieverfahren (MIGS) mittels Excimer-Laser-Technologie, hat das ELIOS™-Verfahren entwickelt, eine implantatfreie Behandlung, die darauf abzielt, den Augeninnendruck bei Glaukom-Patienten zu senken und gleichzeitig die mit traditionellen Operationen verbundenen Risiken zu minimieren.
Die Technologie ist momentan CE-zertifiziert und in der Europäischen Union erhältlich, während die FDA-Zulassung in diesem Jahr angestrebt wird. Das Verfahren kann als eigenständige Behandlung oder zusammen mit einer Katarakt-Operation durchgeführt werden und bietet aufgrund seiner relativen Einfachheit im Vergleich zu implantatbasierten MIGS ein breiteres Einführungspotenzial. Die Akquisition stärkt die Position von Bausch + Lomb im 2,5 Milliarden US-Dollar umfassenden Glaukom-Behandlungsmarkt und adressiert eine Erkrankung, die weltweit über 76 Millionen Menschen betrifft.
- Technology is CE-marked and already commercialized in the European Union
- Addresses a large $2.5 billion glaucoma treatment market
- Versatile procedure that can be performed standalone or with cataract surgery
- Simpler surgical procedure compared to implant-based alternatives, potentially enabling broader adoption
- FDA approval still pending in the U.S. market
- Faces competition in an established MIGS market
Insights
The acquisition of ELIOS Vision significantly strengthens Bausch + Lomb's position in the
The CE mark approval in Europe provides immediate revenue potential, while pending FDA approval could unlock the lucrative US market. The technology's simplified surgical procedure compared to implant-based alternatives suggests potential for rapid adoption among surgeons, which could accelerate market penetration and revenue growth. With glaucoma affecting over 76 million people globally, the addressable market opportunity is substantial.
This strategic acquisition enhances Bausch + Lomb's competitive positioning in the high-margin ophthalmology segment. The implant-free MIGS technology offers significant cost advantages over traditional implant-based procedures, potentially improving profit margins. The acquisition aligns with BLCO's strategy to expand its surgical portfolio and could drive meaningful revenue synergies through the company's established global commercial infrastructure.
While financial terms weren't disclosed, the acquisition's impact on BLCO's market position in the growing glaucoma space could be substantial. The simplified surgical approach could accelerate market adoption, potentially leading to faster revenue ramp-up compared to traditional MIGS technologies. The pending FDA approval represents a significant near-term catalyst that could drive shareholder value.
The MIGS market is experiencing rapid growth due to aging populations and increasing prevalence of glaucoma. ELIOS Vision's innovative approach addresses key market barriers including surgical complexity and patient acceptance. The technology's versatility as both standalone and combination therapy expands the addressable market beyond traditional MIGS procedures.
The acquisition positions BLCO to capitalize on the shift toward minimally invasive procedures in ophthalmology. The implant-free approach could particularly resonate in emerging markets where cost considerations often limit adoption of premium-priced implant-based solutions. The potential market expansion opportunity is significant, given the global prevalence of glaucoma and the technology's broader surgeon adoption profile.
Outcome’s strategic advisory and investment banking played a critical role in the inception, growth and success of ELIOS Vision
ELIOS Vision developed the ELIOS™ procedure, a disruptive and innovative excimer laser-based MIGS. This implant-free procedure is designed to reduce intraocular pressure (IOP) in glaucoma patients while minimizing risks associated with traditional surgeries or implant-based MIGS. ELIOS Vision’s technology is CE-marked and marketed and sold in the European Union, and is seeking
Dr. Oded Ben-Joseph, Managing Partner at Outcome Capital, commented, “Affecting over 76 million people globally, glaucoma is a devastating, complex disease, and patients are in desperate need for effective and safe alternatives to traditional treatments. At Outcome, we recognized the potential for Elios’ technology to impact patient care in 2019, when we began working together to elevate their market position. We believe this acquisition will significantly enhance Bausch + Lomb’s glaucoma portfolio and congratulate the entire Elios team on this significant accomplishment.”
Outcome Capital’s involvement with ELIOS Vision exemplifies the transformative impact that specialized strategic advisory firms can have on emerging life sciences companies. By providing expert guidance during critical growth stages—ranging from financing rounds to acquisition preparation—Outcome Capital helped unlock the full potential of ELIOS Vision’s groundbreaking MIGS technology. Outcome Capital’s efforts secured funding and enhanced operational readiness, and also helped position ELIOS Vision as a leader in next-generation glaucoma treatments.
“Outcome Capital helped develop a compelling narrative around ELIOS Vision’s value proposition ensuring that ELIOS was properly capitalized through multiple rounds of financing to support research and development as well as manufacturing and productization. This approach positioned ELIOS Vision as a leader in next-generation glaucoma treatments, thereby making the company an attractive acquisition target for larger players in the ophthalmology space,” commented Arnold Freedman, Managing Partner at Outcome Capital.
About Outcome Capital
Outcome Capital is a highly specialized life sciences and healthcare advisory and investment banking firm, providing innovative companies with a value-added, market-aligned approach to mergers & acquisitions, partnering and corporate finance. The firm leverages its proven ‘strategy-led execution’ approach to value enhancement by assisting management teams and their boards in navigating both financial and corporate markets and implementing the best path for success. The firm’s strength stems from its multi-disciplinary, industry experts who draw from their broad relationships and a wide range of scientific, operational, strategic and transactional expertise across the value chain. Comprised of former CEOs, business development executives, venture capitalists, PhD/MD-level scientists and clinicians, and experienced commercialization experts, Outcome’s team is driven to propel innovation from bench to bedside.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250109505589/en/
Outcome Capital – Media
Michelle Linn
Linnden Communications
michelle@linndencom.com
Outcome Capital
Steve Holstein
SHolstein@outcomecapital.com
Source: Outcome Capital, LLC
FAQ
What is the market size for glaucoma treatment that BLCO is targeting with the Elios Vision acquisition?
When will Elios Vision's MIGS technology receive FDA approval following BLCO acquisition?
What are the key advantages of Elios Vision's MIGS technology acquired by BLCO?
Where is Elios Vision's MIGS technology currently approved and marketed?
